PharSafer adopts Oracle’s cloud solution for pharmacovigilance

By Staff Reporter

- Last updated on GMT

(Image: Getty/Marharyta Marko)
(Image: Getty/Marharyta Marko)

Related tags: PharSafer, Oracle, Oracle Argus Cloud, Pharmacovigilance, Cloud software

The CRO will utilize the platform to provide clinical and post-marketing drug safety services to clients.

According to PharSafer, a UK-based clinical research organization (CRO), employing the cloud-based software will allow it to exchange data with the market authorization holders. With the data being hosted in the cloud, it will allow the partners to utilize the system without the hurdle of differing IT systems.

Oracle Argus Cloud allows for the processing, analyzing, and reporting of adverse event cases, whether pre- or post-approval, internationally.

The last factor is of significance to PharSafer, as it has clients across seven continents and operates a 24-hour service.

In addition, Oracle notes that it is possible to integrate AI and machine learning tools to automate certain safety processes.

Alongside the deal to use Oracle’s platform, PharSafer will also join the ‘Oracle Health Sciences Safety Consortium’ – which has been organized to increase collaboration between those using Oracle’s services to participate in meetings, events, and working groups to ‘accelerate safety solutions’.

Oracle has signed a number of partnerships deal over the last year, as it broadens the scope of its data management platforms to streamline clinical trial planning​, use of digital​ and database construction​.

Related news

Show more

Related products

show more

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us

Products

View more

Webinars